Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK
A Phase 1/2 Study of Mirdametinib and Vinblastine for Newly Diagnosed or Previously Untreated Patients With Pediatric Low-grade Glioma and Activation of the MAPK Pathway
St. Justine's Hospital
50 participants
Jan 12, 2026
INTERVENTIONAL
Conditions
Summary
This is a 3-part open-label study (feasibility phase, treatment phase and follow-up phase) of orally administered mirdametinib in combination with intravenous vinblastine chemotherapy in patients with PLGG with activation of MAPK pathway. Feasibility Phase: The maximum tolerated/recommended phase 2 dose (MTD/RP2D) of the mirdametinib plus vinblastine combination will be assessed using a modified Rolling-6 design. Treatment Phase: Patients will receive mirdametinib twice daily (continuously) at a fixed dose (2mg/m2 po BID up to 4 mg BID) for a total of 13 cycles (28 days cycle). Weekly intravenous vinblastine at MTD will be given for a total of 17 cycles. If adverse events occur, two dose reductions are allowed. Follow-up Phase: Following the end of treatment, patients will be scheduled for a follow-up visit every 6 months for 36 months to evaluate PFS, TTP and OS.
Eligibility
Inclusion Criteria13
- Signed written informed consent prior to study participation.
- Study activities compliance: must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study, including disease assessment by contrast enhanced MRI.
- Aged ≥ 2 years to ≤ 25 years when starting mirdametinib.
- BSA ≥ 0,40m2
- Diagnosis:
- Participants must have PLGG with NF1 gene mutation (based on clinical NIH criteria, germline NF1 mutation or molecular analysis of the tumor) or PLGG with KIAA1549-BRAF fusion (based on molecular analysis of the tumor) or PLGG with evidence of MAPK pathway alteration with the exception of patients with BRAF V600E mutation (based on molecular analysis of the tumor).
- Tumor tissue is required (at minimum, paraffin-embedded tissue block and additionally fresh frozen tissue \[if available\]). Patients with NF1 and Low Grade Glioma (LGG) can still be enrolled without tissue if no surgery or biopsy was conducted.
- Baseline MRI.
- Life expectancy greater than 6 months.
- Lansky/Karnofsky score ≥ 50.
- Normal organ and marrow function (see study protocol for specifics).
- Female and male patients of fertile age must agree to use highly effective contraceptive measures.
- Must be able to ingest by mouth and retain entirely the administered medication. Mirdametinib can not be administered via nasogastric tube or gastrostomy tube.
Exclusion Criteria12
- Patients who are receiving other investigational agents.
- Cardiac: QTcB ≥ 480 msec or an absolute resting left ventricular ejection fraction (LVEF) of ≤ 49%.
- Patients who have any other malignancy, except if the other primary malignancy is neither currently clinically significant nor requiring active intervention.
- Tumor with BRAF V600E mutation.
- Patients who received previous systemic or radiotherapy treatment.
- Other severe and uncontrollable medical disease
- Blood pressure higher than 95th percentile for patient's age, height and gender.
- Increased risk of serious retinopathy and retinal vein occlusion.
- Known diagnosis of human immunodeficiency virus infection, hepatitis B or C.
- Previous major surgery within 2 weeks.
- History of allergic reactions to compounds of similar chemical or biological composition to mirdametinib.
- Pregnant or breastfeeding.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will receive orally administered mirdametinib in combination with intravenous vinblastine chemotherapy
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06666348